The 24th International AIDS Conference (AIDS 2022), 29 July-2 August 2022, Montreal, Canada and virtually

第 24 届国际艾滋病大会 (AIDS 2022)，2022 年 7 月 29 日至 8 月 2 日，加拿大蒙特利尔

• 批准号: 10481133
• 负责人: Christopher C. Beyrer
• 金额: $ 88.5万
• 依托单位: IAS
• 依托单位国家: 美国
• 财政年份: 2022
• 资助国家: 美国
• 起止时间: 2022-04-19 至 2023-03-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/10481133
• 关键词: 2019-nCoV; AIDS prevention; AIDS/HIV problem; Acquired Immunodeficiency Syndrome; Address; Advocate; Affect; Antiviral Therapy; Area; Attention; Basic Science; Behavioral Research; COVID-19; COVID-19 pandemic; COVID-19 pandemic effects; COVID-19 vaccine; Canada; Caring; Child; Clinical Research; Communities; Consensus; Country; Data; Development; Discipline; Discrimination; Disease Progression; Disease remission; Economics; Environment; Epidemic; Epidemiology; Face; Financial Support; Fostering; Goals; HIV; HIV Infections; HIV vaccine; HIV/TB; Health; Health system; Homophobia; Human Rights; Hybrids; Immunization; Impairment; Incidence; Indigenous; Injectable; International; International AIDS; Intervention; Investments; Knowledge; Laws; Lead; Leadership; Learning; Life Expectancy; Modeling; Monitor; Morbidity - disease rate; Oral; Outcome; Participant; Pathogenesis; Persons; Policies; Politics; Prevention; Prevention approach; Preventive vaccine; Privatization; Research; Research Design; Research Personnel; Resources; Risk; SARS-CoV-2 infection; Science; Science Policy; Scientist; Services; Social Behavior; System; Technology; Telemedicine; Training; Translational Research; Travel; United Nations; Update; Vaccines; Viral hepatitis; Work; Youth; co-infection; community based participatory research; comorbidity; criminal behavior; design; economic determinant; health disparity; illicit drug use; implementation barriers; implementation research; implementation science; innovation; low and middle-income countries; marginalized population; multidisciplinary; neglect; next generation; novel; pandemic disease; pandemic preparedness; patient oriented; person centered; prevent; programs; racial and ethnic disparities; response; same-sex partnership; service delivery; sex; social; social stigma; success; symposium; synergism; transmission process; transphobia; virtual

Project Summary The advances in HIV science across the past 40 years have been remarkable, with near normal life expectancy for persons on antiviral therapy and ever widening access to prevention, treatment and care. However, we do not have an effective HIV vaccine or a cure for the 37 million people living with HIV infection worldwide. The June 2021 United Nations Political Declaration on HIV and AIDS sets new targets and offers welcome clarity on the breadth of policy interventions and resource investments required to meet these objectives. But these will only become a reality if evidence informs policy and scientific innovation continues to provide ever better solutions to remaining biomedical, socio-behavioral and implementation challenges. A global convening bringing together scientists, clinicians, affected community leadership, implementers, donors, and political leaders is thus urgently needed to critically define future research agendas, shift new evidence to action and chart a new consensus on achieving the still elusive goal of pandemic control of HIV. The theme of AIDS 2022, “Re-engage & follow the science” epitomizes this urgency. Recognizing that uneven rollout of COVID-19 vaccines will likely prevent many key stakeholders particularly from countries with a high burden of HIV from travelling internationally, AIDS 2022 will be a fully hybrid conference (29 July-2 August 2022). In addition to the virtual conference platform, Montreal will provide a compelling venue for AIDS 2022 as a leading center of HIV science, with a view to the progressive Canadian policy environment for those at risk and in recognition of Canadian leadership in global cooperation to address the epidemic. Specific aims for AIDS 2022 are to: 1. Accelerate scientific discovery to drive innovation across the HIV prevention and treatment cascades, including pathogenesis, transmission, vaccines, remission and a functional cure; long-acting oral and injectable treatment and prevention technologies, including rings for prevention; integrated and differentiated models of care; and analyses of structural and economic determinants of health. 2. Accelerate updates to treatment guidance especially for low and middle-income countries, infected children and persons with HIV, TB, viral hepatitis and COVID-19 infection. 3. Facilitate the adaptation of innovations from the response to COVID-19 across science, policy and practice and consolidating good practice for pandemic preparedness, and immunization efforts including new partnerships between public and private stakeholders and learnings from adaptations from the HIV response that accelerated the response to COVID-19. 4. Advance core components of implementation science research that address the challenges and opportunities of integration across a range of epidemic settings and in the COVID-19 era, including findings from community-led research, monitoring and innovations in service delivery, including telemedicine. 5. Address HIV vulnerability and determinants of disease progression among key and marginalized populations, including novel interventions and implementation science to reduce stigma and discrimination, including intersectional stigmas of HIV, homophobia, transphobia, and ethnic and racial disparities, including those among indigenous/first nation communities and impact of criminalization of behaviours including same- sex relationships, illicit drug use, and sex work. 6. Draw attention to enduring gaps in the HIV response, such as areas where greater investment is needed in research and person-centered service delivery, and where the needs of communities remain neglected. The scientific program will consist of six tracks: Track A/Basic and Translational Research; Track B/Clinical Research; Track C/Epidemiology and Prevention Science; Track D/Social and Behavioral Research; Track E/ Implementation Research, Economics, Systems and Synergies with other Health and Development Sectors; and Track F/Political research, law, policy and human rights. While the scientific program of the conference is developed by international track committees that represent different disciplines and areas of science, cross- cutting aspects will be covered in plenary talks that also connect the scientific tracks with community and leadership perspectives. Additionally, bridging sessions are designed to cut across at least two of the scientific tracks to provide opportunities for multi-disciplinary, multi-perspective dialogues, often using interactive formats. The participation of young researchers, basic scientists and researchers in related fields such as non- communicable diseases will be strengthened by active solicitation of relevant science and the provision of specific financial support, in addition to remote-access options. Key science from the conference will be disseminated and discussed in regional contexts following AIDS 2022.

项目概要 过去 40 年来，艾滋病毒科学取得了显着的进步，预期寿命接近正常人 然而，我们确实这样做了。 目前还没有有效的艾滋病毒疫苗或治愈方法来治疗全世界 3700 万艾滋病毒感染者。 2021 年 6 月《联合国关于艾滋病毒和艾滋病的政治宣言》设定了新的目标，并提供了令人欢迎的明确内容 实现这些目标所需的政策干预和资源投资的广度。 只有当证据为政策提供依据并且科学创新不断提供更好的结果时，这一目标才能成为现实 解决剩余的生物医学、社会行为和实施挑战。 因此，科学家、人群、受影响的社区领导、实施者、捐助者和政治领导人一起 迫切需要批判性地定义未来的研究议程，将新的证据转化为行动并制定新的计划 就实现控制艾滋病毒大流行这一仍难以实现的目标达成共识 2022年艾滋病主题是“重新参与”。 并遵循科学”集中体现了这种紧迫性。 认识到 COVID-19 疫苗的不均衡推广可能会阻止许多关键利益相关者，特别是 由于国际旅行而导致艾滋病毒负担较高的国家，2022年艾滋病将是一次完全混合的会议 （2022 年 7 月 29 日至 8 月 2 日）除了虚拟会议平台外，蒙特利尔还将提供一个引人注目的场地。 艾滋病 2022 作为艾滋病毒科学的领先中心，以期改善加拿大的政策环境 为那些面临风险的人提供帮助，并承认加拿大在应对这一流行病的全球合作中发挥的领导作用。 2022 年艾滋病防治的具体目标是： 1. 加速科学发现，推动艾滋病毒预防和治疗级联的创新， 包括发病机制、传播、疫苗、缓解和长效口服和功能性治疗； 注射治疗和预防技术，包括综合和差异化预防环； 护理模式；以及健康的结构和经济决定因素的分析。 2. 加快更新治疗指南，特别是针对感染者的低收入和中等收入国家 儿童和艾滋病毒、结核病、病毒性肝炎和 COVID-19 感染者。 3. 促进应对 COVID-19 的创新在科学、政策和领域的应用 实践和巩固大流行防范和免疫工作的良好做法，包括新的 公共和私人利益相关者之间的伙伴关系以及从艾滋病毒应对措施的适应中吸取的经验教训 加速了对 COVID-19 的反应。 4. 推进实施科学研究的核心组成部分，以应对挑战和 在各种流行病环境和 COVID-19 时代进行整合的机会，包括调查结果 来自社区主导的服务提供研究、监测和创新，包括远程医疗。 5. 解决关键和边缘群体中艾滋病毒脆弱性和疾病进展的决定因素 人口，包括减少耻辱和歧视的新干预措施和实施科学， 包括艾滋病毒、同性恋恐惧症、变性恐惧症以及民族和种族差异的交叉耻辱，包括 土著/原住民社区中的那些行为以及将行为定为刑事犯罪的影响，包括同样的行为 性关系、非法药物使用和性工作。 6. 提请注意艾滋病毒应对工作中长期存在的差距，例如需要加大投资的领域 在研究和以人为本的服务提供方面，社区的需求仍然被忽视。 科学计划将包括六个方向：A方向/基础和转化研究；B方向/临床； 研究；C/流行病学和预防科学；D/社会和行为研究； 实施研究、经济学、系统以及与其他卫生和发展部门的协同作用； Track F/政治研究、法律、政策和人权，而会议的科学议程是。 由代表不同学科和科学领域的国际田径委员会制定， 全体会议将讨论切割方面的内容，这些会议还将科学轨道与社区和 此外，衔接会议旨在跨越至少两个科学领域。 轨道提供多学科、多视角对话的机会，通常使用互动形式。 青年研究人员、基础科学家和非相关领域研究人员的参与 将通过积极征求相关科学知识并提供 除了会议的远程访问选项之外，还将提供具体的财政支持。 2022 年艾滋病之后在区域范围内传播和讨论。